Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†

authors

• Chauffert B.
• Feuvret L.
• Bonnetain F.
• Taillandier L.
• Frappaz Didier
• Taillia H.
• Schott R.
• Honnorat J.
• Fabbro M.
• Tennevet I.
• Ghiringhelli F.
• Guillamo J.
• Durando X.
• Castera D.
• Frenay M.
• Campello C.
• Dalban C.
• Skrzypski J.
• Chinot O.

more information